Pfizer (NYSE:PFE) stock is a biopharmaceutical firm that had a magnificent breakout in 2021 as the worst of the pandemic sent ...

Pfizer’s 7%+ yield is tempting, but rising political, regulatory, and business risks threaten its stability and growth ...

Pfizer is undervalued as markets fixate on its patent cliff, overlooking strong cash flows, pipeline upside, and a 7% yield.

The company’s strategy focuses on steadily increasing its dividend, reinvesting in the business with strong financial returns, and carrying out value-driven share buybacks.

Pfizer’s first quarter results drew a positive market response as management emphasized margin improvement and disciplined ...

Pharma/biotech giants Pfizer PFE and Bristol Myers BMY boast of a dominant position in the lucrative oncology space. Oncology ...

Despite recent declines, we believe Pfizer stock is a compelling buy right now, with its current price of around $23 likely reflecting existing concerns.

Pfizer's (NYSE:PFE) stock is up by a considerable 7.5% over the past month. However, we decided to pay attention to ...

Its dividend: The stock recently yielded a whopping 7.3%. That's hard to beat and will generate around $730 for every $10,000 you have invested in Pfizer. CFO David Denton called the company’s ...

Social media is teeing off on Kansas City Chiefs tight end Travis Kelce after a report revealed how much he gets from Pfizer.

This was the stock's third consecutive day of losses.